207 related articles for article (PubMed ID: 35840113)
1. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy.
Thomas MC; Chen YH; Fite E; Pangilinan A; Bubelo K; Spektor A; Balboni TA; Huynh MA
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):747-761. PubMed ID: 35840113
[TBL] [Abstract][Full Text] [Related]
2. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
[TBL] [Abstract][Full Text] [Related]
6. Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: A single-center study.
He X; Zhang P; Li Z; Bi F; Xu F; Wang X; Shen Y; Li Q; Qiu M
Medicine (Baltimore); 2018 Oct; 97(40):e12601. PubMed ID: 30290630
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis.
Poon I; Erler D; Dagan R; Redmond KJ; Foote M; Badellino S; Biswas T; Louie AV; Lee Y; Atenafu EG; Ricardi U; Sahgal A
JAMA Netw Open; 2020 Nov; 3(11):e2026312. PubMed ID: 33196810
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
11. Repeat stereotactic body radiotherapy for oligometastatic disease.
Willmann J; Adilovic S; Vlaskou Badra E; Christ SM; Ahmadsei M; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2023 Jul; 184():109671. PubMed ID: 37059336
[TBL] [Abstract][Full Text] [Related]
12. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
13. Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases.
Voglhuber T; Kessel KA; Oechsner M; Vogel MME; Gschwend JE; Combs SE
BMC Cancer; 2020 Jun; 20(1):536. PubMed ID: 32513136
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes.
Glemarec G; Lacaze JL; Cabarrou B; Aziza R; Jouve E; Zerdoud S; De Maio E; Massabeau C; Loo M; Esteyrie V; Ung M; Dalenc F; Izar F; Chira C
Breast; 2023 Feb; 67():102-109. PubMed ID: 36709639
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.
Bhattacharya IS; Woolf DK; Hughes RJ; Shah N; Harrison M; Ostler PJ; Hoskin PJ
Br J Radiol; 2015 Apr; 88(1048):20140712. PubMed ID: 25679321
[TBL] [Abstract][Full Text] [Related]
16. Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases.
Yeung R; Hamm J; Liu M; Schellenberg D
Radiat Oncol; 2017 Jun; 12(1):105. PubMed ID: 28637480
[TBL] [Abstract][Full Text] [Related]
17. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcomes Among Patients Treated With Stereotactic Body Radiation Therapy to Femur Metastases for Oligometastatic Disease Control or Reirradiation: Results From a Large Single-Institution Experience.
Kwan C; Chen YH; Killoran JH; Ferrone M; Marcus KJ; Tanguturi S; Balboni TA; Spektor A; Huynh MA
Adv Radiat Oncol; 2024 Apr; 9(4):101439. PubMed ID: 38419821
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
